Introduction to Therapeutic Drug Monitoring and Chromatography

Advances in Chromatographic Techniques for Therapeutic Drug Monitoring

Volumn , Issue , 2009, Pages 1-38

  Dasgupta, Amitava ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85011782603     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420067590-7     Document Type: Chapter

References (118)

1. Hersh EV, Pinto A, Moore PA. 2007. Adverse drug interactions involving common prescription and over the counter analgesics. Clin Ther 29: 2477-2497.
2. Watson I, Potter J, Yatscoff R, Fraser A et al. 1997. Editorial. Ther Drug Monit 19: 125.
3. Peterson GM, Khoo BH, von Witt RJ. 1991. Clinical response in epilepsy in relation to total and free serum levels of phenytoin. Ther Drug Monit 13: 415-419.
4. Rajendran SD, Rao YM, Thanikachalam S, Muralidharan TR, Anbalagan M et al. 2005. Comparison of target concentration intervention strategy with conventional dosing of digoxin. Indian Heart J 57: 265-267.
5. Pawinski T, Pulik P, Gralak B, Horban A. 2008. Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. Acta Pol Pharm 65: 93-100.
6. Chugh SS, Socoteanu C, Reinier K, Waltz J et al. 2008. A community-based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 121: 66-71.
7. Gillisen A. 2007. Patient’s adherence in asthma. J Physiol Pharmacol 58 (suppl 5, Pt 1): 205-222.
8. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC et al. 2008. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the sub commission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 49: 1239-1276.
9. Bigger JT, Leahey EB Jr. 1982. Quinidine and digoxin: an important interaction. Drugs 24: 229-239.
10. Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL. 1976 Ototoxicity of amikacin. Antimicrob Ag Chemother 9: 956-961.
11. Duffull SB, Begg EJ. 1994. Vancomycin toxicity: what is the evidence for dose dependence? Adverse Drug React Toxicol Rev 13: 103-114.
12. Begg EJ, Barclay ML, Kirkpatrick C. 1999. The therapeutic monitoring of antimicrobial agents [review]. J Clin Pharmacol 47: 23-30.
13. Ryback MJ, Albrecht LM, Boike SC, Chandrasekar PH. 1990. Nephrotoxicity of vancomycin: alone or with an aminoglycoside. J Antimicrob Chemother 25: 679-687.
14. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. 1987. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 83: 1091-1096.
15. Florence AT, Jani PU. 1994. Novel oral drug formulations: their potential in modulating adverse effects. Drug Saf 10: 233-266.
16. Tedesco-Silva H, Bastien MC, Choi L, Felipe C et al. 2005. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 37: 852-855.
17. van Hoogdalem E, de Boer AG, Breimer DD. 1991. Pharmacokinetics of rectal drug administration, Part I: General considerations and clinical applications of centrally active drugs. Clin Pharmacokinet 21: 11-26.
18. Fischer JH, Patel TV, Fischer PA. 2003. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet 42: 33-58.
19. Pajouhesh H, Lenz GR. 2005. Medicinal chemicals properties of successful central nervous system drugs. NeuroRx 2: 541-553.
20. Ningaraj NS. 2006. Drug delivery to brain tumors: challenges and progress. Expert Opin Drug Deliv 3: 499-509.
21. Morgan MM, Khan DA, Nathan RA. 2005. Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines. Ann Pharmacother 39: 2056-2064.
22. Rollins DE, Klaassen CD. 1979. Biliary excretion of drugs in man. Clin Pharmacokinet 4: 368-379.
23. Evans WE, Relling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491.
24. Zager UM, Turpeinen M, Klein K, Schwab M. 2008. Functional pharmacogenetics/genomics of human cytochrome P450 involved in drug biotransformation. Anal Bioanal Chem Aug 10 [E-pub ahead of print].
25. Rollason V, Samer C, Piguet V, Dayer P et al. 2008. Pharmacogenomics of analgesics: toward the individualization of prescription. Pharmacogenomics 9: 905-933.
26. van Schaik RH. 2008. CYP450 pharmacogenetics for personalized cancer therapy. Drug Resist Updat 11: 77-98.
27. Vizirianakis IS. 2004. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Curr Drug Deliv 1: 73-80.
28. de Leon J. 2006. Amplichip CYP450 test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 6: 277-286.
29. Schwartz JB. 2003. The influence of sex on pharmacokinetics. Clin Pharmacokinet 42; 107-121.
30. Brosen K. 2007. Sex differences in pharmacology [in Danish]. Ugeskr Laeger 169: 2408-2411.
31. Rugstad HE, Hundal O, Holme I, Herland OB et al. 1986. Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clin Rheumatol 5: 389-398.
32. Gex-Fabry M, Balant-Georgia AE, Balant LP, Garrone G. 1990. Clomipramine metabolism: model based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 19: 241-255.
33. Walle T, Walle UK, Cowart TD, Conradi EC. 1989. Pathway selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 46: 257-263.
34. Lew KH, Ludwig EA, Milad MA, Donovan K. 1993. Gender based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 54: 402-414.
35. Wolbold R, Klein K, Burk O, Nussler AK et al. 2003. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38: 978-988.
36. Rademaker M. 2001. Do women have more adverse drug reactions? Am J Clin Dermatol 2: 349-351.
37. Miners JO, Attwood J, Birkett DJ. 1983. Influence of sex and oral contraceptives on paracetamol metabolism. Br J Clin Pharmacol 16: 503-509.
38. Noe KH. 2007. Gender specific challenges in the management of epilepsy in women. Semin Neurol 27: 331-339.
39. Pauly JR. 2008. Gender specific differences in tobacco smoking dynamics and the neuropharmacological actions of nicotine. Front Biosci 13: 505-516.
40. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
41. Terrell KM, Heard K, Miller DK. 2006. Prescribing to older ED patients. Ann J Emerg Med 24: 468-478.
42. Dasgupta A. 2007. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta 377: 1-13.
43. Joannidis M 2004. Drug-induced renal failure in the ICU. Int J Artif Organs 27: 1034-1042.
44. Izzedine H, Launay-Vacher V, Deray G. 2005. Antiviral drug induced nephrotoxicity. Am J Kidney Dis 45: 804-817.
45. Choudhury D, Ahmed Z. 1997. Drug-induced nephrotoxicity. Med Clin North Am 81: 705-717.
46. Verbeeck RK. 2008. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Phramacol September 2 [E-pub ahead of print].
47. Cheng PY, Morgan ET. 2001. Hepatic cytochrome P 450 regulation in disease states. Curr Drug Metab 2: 165-183.
48. Villeneuve JP, Pichette V. 2004. Cytochrome P450 and liver disease. Curr Drug Metab 5: 273-282.
49. Klotz U. 2007. Antiarrhythmics: elimination and dosage considerations in hepatic impairment. Clin Pharmacokinet 46: 985-996.
50. Trotter JF, Osborne JC, Heller N, Christians U. 2005. Effect of hepatitis C infection on tacrolimus does and blood levels in liver transplant recipients. Aliment Pharmacol Ther 22: 37-44.
51. Zimmermann JJ, Lasseter KC, Lim HK, Harper D et al. 2005. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 45: 1368-1372.
52. Ng CY, Ghabrial H, Morgan DJ, Ching MS et al. 2000. Impaired elimination of propoanolol due to right heart failure: drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity. Drug Metab Dispo 28: 1217-1221.
53. Benowitz NL, Meister W. 1976. Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1: 389-405.
54. Boucher BA, Wood GC, Swanson JM. 2006. Pharmacokinetic changes in critical illness. Crit Care Clin 22: 255-271.
55. Croxson MS, Ibbertson HK. 1975. Serum digoxin in patients with thyroid disease. Br Med J 3 (5983): 566-568.
56. Sarich TC, Wright JM. 1996. Hypothyroxinemia and phenytoin toxicity: a vicious circle. Drug Metabol Drug Interact 13: 155-160.
57. Haas M, Kletzmayer J, Staudinger T, Bohmig G et al. 2000. Hypothyroidism as a cause of tacrolimus intoxication and acute renal failure: a case report. Wien Klin Wochenschr 112: 939-941.
58. Kurnik D, Loebstein R, Farfel Z, Ezra D et al. 2004. Complex drug-drug disease interactions between amiodarone, warfarin and the thyroid gland. Medicine (Baltimore) 83: 107-113.
59. Kellett HA, Sawers JS, Boulton FE, Cholerton S et al. 1986. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 58: 43-51.
60. Loebstein R, Koren G. 2002. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit 24: 15-22.
61. Rakhmanina N, van den Anker, Soldin SJ. 2004. Safety and pharmacokinetics of antiretroviral therapy during pregnancy. Ther Drug Monit 26: 110-115.
62. Anderson GD. 2005. Pregnancy induced changes in pharmacokinetics: a mechanistic based approach. Clin Pharmacokinet 44: 989-1008.
63. Tomson T. 2005. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast feeding. Ther Drug Monit 27: 718-721.
64. Pennell PB, Newport DJ, Stowe ZN, Helmers SL et al. 2004. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 27: 292-295.
65. Soldin OP. 2006. Thyroid function testing in pregnancy and thyroid diseases: trimester-specific reference intervals. Ther Drug Monit 28: 8-11.
66. Koren G, Soldin O. 2006. Therapeutic drug monitoring of antithyroid drugs during pregnancy. Ther Drug Monit 28: 12-13.
67. Hodge LS, Tracey TS 2007. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 3: 557-571.
68. Mucklow JC. 1986. The fate of drugs in pregnancy. Clin Obstet Gynacecol 13: 161-175.
69. Oesterheld JR. 1998. A review of developmental aspects of cytochrome P 450. J Child Adolesc Psychopharmacol 8: 161-174.
70. Oineiro-Carrero VM, Pineiro EO. 2004. Liver [Review]. Pediatrics 113 (4 Suppl) 1097-1106.
71. Perucca E. 2005. Pharmacokinetics variability of new antiepileptic drugs at different age. Ther Drug Monit 27: 714-717.
72. Paap CM, Nahata MC. 1990. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 19: 280-318.
73. Williams BS, Ransom JL, Gal P, Carlos RQ et al. 1997. Gentamicin pharmacokinetics in neonates with patent ductus arteriosus. Crit Care Med 25: 272-275.
74. Brazier JL, Salle B. 1981. Conversion of theophylline to caffeine by the human fetus. Semin Perinatol 5: 315-320.
75. Zevin S, Benowitz NL. 1999. Drug interactions with tobacco smoking: an update. Clin Pharmacokinetic 36: 425-438.
76. Kroon LA. 2006. Drug interactions and smoking: raising awareness for acute and critical care provider. Crit Care Nurs Clin N Am 18: 53-62.
77. Lee BL, Benowitz NL, Jacob P. 1987. Cigarette abstinence, nicotine gum and theophylline disposition. Ann Intern Med 106: 553-555.
78. Colucci VJ, Knapp JE. 2001. Increase in International normalization ratio associated with smoking cessation. Ann Pharmacother 35: 385-386.
79. Creekmore FM, Lugo RA, Weiland KJ. 2004. Postoperative opiate analgesic requirements for smokers and non smokers. Ann Pharmacother 38: 949-953.
80. Koski A, Vuori E, Ojanpera I. 2005. Relation of postmortem blood alcohol and drug concentrations in fetal poisonings involving amitriptyline, propoxyphene and promazine. Hum Exp Toxicol 24: 389-396.
81. Song BJ. 1996. Ethanol inducible cytochrome P450 (CYP2E1): biochemistry, molecular biology and clinical relevance-an update. Alcoholism Clin Exp Res 20 (Supply 8): 136A-146A.
82. Jimenez-Lopez JM, Cederbaum AI. 2005. CYP2E1 dependent oxidative stress and toxicity: role in ethanol induced liver injury. Expert Opin Drug Metab Toxicol 1: 671-685.
83. Weathermon R, Crabb DW. 1999. Alcohol and medication interactions. Alcohol Res Health 23: 40-54.
84. Caballeria J, Baraona E, Deulofeu R, Hernandez-Munoz R et al. 1991. Effect of H-32 receptor agonists on gastric alcohol dehydrogenase activity. Diges Dis Sci 36: 1673-1679.
85. Fujita K. 2004. Food drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20: 195-217.
86. Evans AM. 2000. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 22: 131-136.
87. Walter-Sack I, Klotz U. 1996. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 31: 47-64.
88. Fegan TC, Walle T, Oexmann MJ, Walle UK et al. 1987. Increased clearance of propranolol and theophylline by high-protein compared with high carbohydrate diet. Clin Pharmacol Ther 41: 402-406.
89. Bailey DG, Spence JD, Munoz C, Arnold JM. 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268-269.
90. Saito M, Hirata-Koizumi M, Matsumoto M, Urano T, Hasegawa R. 2005. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies. Drug Saf 28: 677-694.
91. Uno T, Ohkubo T, Sugawara K, Higashiyama A et al. 2000. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystematic elimination at the gut site. Eur J Clin Pharmacol 56: 643-649.
92. Dahan A, Altman H. 2004. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur J Clin Nutr 58: 1-9.
93. Tian R, Koyabu N, Takanaga H, Matsuo H et al. 2002. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 19: 802-809.
94. Paine MF, Widmer WW, Hart HL, Pusek SN. 2006. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83: 1097-1105.
95. Dresser GK, Kim RB, Bailey DG. 2005. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of anion transporting polypeptides. Clin Pharmacol Ther 77: 170-177.
96. Berezkin VG Ed. 1990. Chromatographic Absorption Analysis: selected works of M.S. Tswett. Ellis Horwood, New York.
97. Borgstrom B. 1952. Investigation on lipid separation methods. Separation of phospholipids from natural fat and fatty acids. Acta Physiol Scand 25: 101-110.
98. Izmailov NA, Shraiber MS. 1938. The application of analysis by drop-chromatography to pharmacy. Farmazia 3: 1-7 [in Russian]. (For English translation, see N Pelick, HR Bollinger, and HK Mangold 1966. In JC Giddings and RA Keller eds., Advances in Chromatography. Vol. 3. Mercel Dekker, New York, 85-118.)
99. Plesch J. 1906. About the diazobenzol reaction of bilirubin. Zentrablatt fur Innere Medizin 27: 1-3 [in German]. (For English translation see ED Morgan and ID Wilson. 2004. An early description of paper chromatography. Chromatgraphia 60: 135-136.)
100. Consden R, Gordon AH, Martin AJP. 1944. Qualitative analysis of proteins: a partition chromatographic method using paper. Biochem J 38: 224-232.
101. Martin AJP, Synge RLM. 1941. A new form of chromatogram employing two liquid phases. 1. A theory of chromatography, 2. Application to the micro-determination of the higher monoamino-acids in proteins. Biochem J 35: 1358-1368.
102. James AT, Martin AJP. 1952. Gas-liquid partition chromatography: the separation and micro-estimation of volatile fatty acids from formic acid to dodecanoic acid. Biochem J 50: 679-690.
103. Knox JH. 1966. Evidence for turbulence and coupling in chromatographic columns. Anal Chem 38: 253-261.
104. Horvath CG, Lipsky SR. 1966. Use of liquid ion exchange chromatography for the separation of organic compounds. Nature 211: 748-749.
105. Horvath CG, Preiss BA, Lipsky SR. 1967. Fast liquid chromatography: an investigation of operating parameters and the separation of nucleotides on pellicular ion exchangers. Anal Chem 39: 1422-1428.
106. Roger JC, Rodgers G, Soo A. 1973. Simultaneous determination of carbamazepine (Tegretol) and other anticonvulsants in human plasma by gas-liquid chromatography. Clin Chem 19: 590-592.
107. Kuperberg HJ. 1970. Quantitative estimation of diphenylhydantoin, primidone and Phenobarbital in plasma by gas liquid chromatography. Clin Chim Acta 29: 282-288.
108. Davis HL, Falk KJ, Bailey DG. 1975. Improved method for the simultaneous determinations of Phenobarbital, primidone and diphenylhydantoin in patients’ serum by gas liquid chromatography. J Chromatogr 9: 61-66.
109. Speed DJ, Dickinson SJ, Cairns ER, Kim ND. 2000. Analysis of six anticonvulsant drugs using solid phase extraction deuterated internal standards and gas chromatography-mass spectrometry. J Anal Toxicol 24: 685-690.
110. Pocci R, Dixit V, Dixit VM. 1992. Solid phase extraction and GC/MS confirmation of barbiturates from human urine. J Anal Toxicol 16: 45-47.
111. Kerbusch T, Jeuken MJ, Derraz J, van Putten JW et al. 2000. Determination of ifosfamide, 2 and 3-dechloroethylifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection. Ther Drug Monit 22: 613-620.
112. Minnigh MB, Alvin JD, Zemaitis MA. 1994. Determination of plasma mexiletine levels with gas chromatography-mass spectrometry and selected ion monitoring. J Chromatogr B Biomed Appl 662: 118-122.
113. Dasgupta A, Appenzeller P, Moore J. 1998. Gas chromatography-electron ionization mass spectrometric analysis of serum mexiletine concentration after derivatization with 2, 2, 2-trochloroethyl chloroformate: a novel derivative. Ther Drug Monit 20: 313-318.
114. Dasgupta A, Yousef O. 1998. Gas chromatographic-mass spectrometric determination of serum mexiletine concentration after derivatization with perfluorooctanoyl chloride, a new derivative. J Chromatogr B Biomed Sci Appl 705: 282-288.
115. Subramanian M, Birnbaum AK, Remmel RP. 2008. High speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit 30: 347-356.
116. Verbesselt R, Tjandramaga TB, de Schepper PJ. 1991. High performance liquid chromatographic determination of 12 antiarrhythmic drugs in plasma using solid phase extraction. Ther Drug Monit 13: 157-165.
117. Dasgupta A, Rosenzweig IB, Turgeon J, Raisys VA. 1990. Encainide and metabolites analysis in serum or plasma using a reversed-phase high performance liquid chromatographic technique. J Chromatogr 526: 260-265.
118. Kamberi M, Tsutsumi K, Kotegawa T, Nakamura K et al. 1998. Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection. Clin Chem 44: 1251-1255.